Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies
L Walcher, AK Kistenmacher, H Suo, R Kitte… - Frontiers in …, 2020 - frontiersin.org
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …
T cell-engaging therapies—BiTEs and beyond
ME Goebeler, RC Bargou - Nature Reviews Clinical Oncology, 2020 - nature.com
Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Z Tian, M Liu, Y Zhang, X Wang - Journal of hematology & oncology, 2021 - Springer
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …
has become a promising strategy in clinical management of hematologic malignancies. The …
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
NG Daver, A Maiti, TM Kadia, P Vyas, R Majeti, AH Wei… - Cancer discovery, 2022 - AACR
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
T-cell-engaging bispecific antibodies in cancer
NWCJ van de Donk, S Zweegman - The Lancet, 2023 - thelancet.com
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation
M Dougan, G Dranoff, SK Dougan - Immunity, 2019 - cell.com
The β common chain cytokines GM-CSF, IL-3, and IL-5 regulate varied inflammatory
responses that promote the rapid clearance of pathogens but also contribute to pathology in …
responses that promote the rapid clearance of pathogens but also contribute to pathology in …
Overview of methodologies for T-cell receptor repertoire analysis
Background The T-cell receptor (TCR), located on the surface of T cells, is responsible for
the recognition of the antigen-major histocompatibility complex, leading to the initiation of an …
the recognition of the antigen-major histocompatibility complex, leading to the initiation of an …
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Treatment of relapsed/refractory acute myeloid leukemia
P Bose, P Vachhani, JE Cortes - Current treatment options in oncology, 2017 - Springer
Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …